Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a multi-center, Phase IIa, randomized, double-blind, placebo-controlled study in patients with Alzheimer's Disease (AD).
Full description
This is an exploratory, double-blind, randomized, placebo-controlled phase IIa proof of concept study to evaluate the safety, pharmacodynamics and pharmacokinetics of TW001 in patients with mild AD. Patients will be randomized 1:1 to TW001 and placebo. Treatments will be given in a fasted state once daily for 90 days. The total duration of the clinical trial will be approximately 4 months per patient.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age 55-80 years (both inclusive), male or female.
Body mass index between 18.5 to 33.0 kg/m2 (both inclusive).
Should meet the criteria for early clinical stage Alzheimer's Disease (AD) according to the National Institute on Aging and Alzheimer's Association (NIA-AA) criteria research framework:
(i) Cerebrospinal fluid (CSF) profile consistent with AD (an Aβ42 concentration of <1000 pg/mL AND phosphorylated tau (p-tau) >19 pg/mL, or a ratio of p-tau/Aβ42 of ≥0.020) taken during the screening period prior to the day of the first dose of study medication, or
(ii) Documented evidence of a CSF profile consistent with AD obtained with the previous 12 months, or
(iii) Documented amyloid positron emission tomography (PET) scan evidence acquired within the previous 12 months.
A reliable and competent trial partner/caregiver who can assist and witness dosing and is willing to accompany the patient to all visits. The trial partner/caregiver should understand the nature of the trial and adhere to trial requirements (e.g., visit schedules, evaluations) and confirm this by co-signing the informed consent of the patient or signing of a separate informed consent of the partner/caregiver according to the local requirements.
If a patient is taking medication, supplements or vitamins that may have an influence on oxidative stress, cognition and/or EEG, the dose must be stable at screening for at least one month, and the patient must be willing to remain on the same treatment and dose for the duration of the trial.
A male patient abstains from sexual intercourse, or is vasectomized (> 6 months), or will use a condom with spermicide during sexual intercourse during the trial and for three months after participation in the trial and will abstain from sperm donation during the trial and for three months after participation in the trial.
A female patient should not be of reproductive potential:
A female patient who is not of reproductive potential is defined as one who:
Capable of providing informed consent and complying with trial procedures.
Exclusion criteria
A known history of stroke that is clinically important in the investigator's opinion.
Evidence of a clinically relevant neurological disorder other than AD at screening, including but not limited to: vascular dementia, Parkinson's disease, frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, progressive supranuclear palsy, dementia with Lewy bodies, other types of dementia, neurosyphilis or head trauma with loss of consciousness that led to persistent cognitive deficits.
A history of seizures or epilepsy within the last 5 years before screening.
Evidence of a clinically relevant or unstable psychiatric disorder, based on the 5th edition after text revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5TM) criteria, including schizophrenia or other psychotic disorder, bipolar disorder, major depression, or delirium. Major depression in remission is not exclusionary.
Renal impairment as indicated by a creatinine clearance of less than 50 mL/min as calculated by the Cockcroft Gault equation.
Patient has a history of any of the following conditions:
Presence of any of the following clinical conditions:
History or signs/symptoms of lumbar spine/disc disease including but not limited to scoliosis, herniation, or any other contraindication to lumbar puncture.
History of known sensitivity or intolerability to edaravone, related substances of edaravone, or to any of the excipients.
Current substance or alcohol dependence.
Exposure to any investigational drug within 30 days of the screening visit.
Primary purpose
Allocation
Interventional model
Masking
61 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Frank Ruwe; Anastasia Lili
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal